XOMA (NASDAQ:XOMA) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a report published on Wednesday.

A number of other research analysts have also issued reports on XOMA. Leerink Partnrs reiterated an outperform rating on shares of XOMA in a report on Monday, April 29th. HC Wainwright reissued a buy rating and issued a $74.00 price objective on shares of XOMA in a research note on Tuesday, July 9th. Finally, SVB Leerink assumed coverage on XOMA in a research report on Monday, April 29th. They set an outperform rating and a $40.00 target price for the company.

XOMA Price Performance

Shares of XOMA opened at $28.13 on Wednesday. The company has a quick ratio of 9.45, a current ratio of 9.45 and a debt-to-equity ratio of 1.39. The stock has a market cap of $329.12 million, a PE ratio of -7.18 and a beta of 0.93. XOMA has a 12-month low of $13.48 and a 12-month high of $30.36. The business has a 50-day simple moving average of $25.60 and a two-hundred day simple moving average of $24.76.

Institutional Investors Weigh In On XOMA

Several large investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its holdings in XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,266 shares during the period. Price T Rowe Associates Inc. MD bought a new position in shares of XOMA in the 1st quarter worth about $212,000. Rhumbline Advisers boosted its position in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.